戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1                                 We created a bioartificial adrenal with 3D cell culture conditions by
2          In conclusion, transplantation of a bioartificial adrenal with xenogeneic cells may be a tre
3   To mimic the 3D context of human arteries, bioartificial arteries were engineered from collagen typ
4 very quickly welcoming emerging augmentative bioartificial corticospinal grasping strategies.
5 r advances will need to be made before these bioartificial devices can be considered for routine appl
6  stem-cell research, tissue engineering, and bioartificial devices for the treatment of the heterogen
7 n, multiagent immunosuppressant therapy, and bioartificial devices such as lacrimal gland microdevice
8                                      In this bioartificial endocrine pancreas, the hardware will be r
9 acturing of a regenerative medicine-inspired bioartificial endocrine pancreas.
10 ion of a new-generation, fully human-derived bioartificial endocrine pancreas.
11                                              Bioartificial grafts that provide gas exchange have been
12                                            A bioartificial heart is a theoretical alternative to tran
13                                 Generating a bioartificial heart requires engineering of cardiac arch
14 ent assist devices have driven innovation in bioartificial hearts (BAHs) and cardiac constructs.
15                 This work aims to synthesize bioartificial hydrogel from a blend of sodium alginate (
16      We engineered polyethylene glycol-based bioartificial hydrogel matrices presenting protease-degr
17 ne (PDMS), with which hypoxia in the core of bioartificial islets was alleviated and glucose-stimulat
18                                          The bioartificial kidney (BAK) consists of a conventional he
19                  To assess the effect of the bioartificial kidney and the RAD in septic shock, pigs w
20 l replacement therapy in a tissue-engineered bioartificial kidney comprising both biologic and synthe
21       The development of a tissue-engineered bioartificial kidney consisting of a conventional hemofi
22                Alternatively, an implantable bioartificial kidney could address both problems while e
23 herapeutic approach with a tissue-engineered bioartificial kidney may be a new treatment modality for
24                               An implantable bioartificial kidney requires a bioreactor containing re
25 s, continuous renal replacement therapy, the bioartificial kidney, and peritoneal dialysis in the man
26                                          The bioartificial kidney, combining hemofiltration with a de
27 f chronic kidney disease, the development of bioartificial kidneys that mimic healthy kidney function
28                    We have developed a novel bioartificial liver (BAL) composed of porcine hepatocyte
29  from lymphocytes of patients treated with a bioartificial liver (BAL) containing pig hepatocytes and
30   The purpose of this study was to develop a bioartificial liver (BAL) to treat patients with severe
31 s an extracorporeal porcine hepatocyte-based bioartificial liver (BAL).
32 dy source of metabolic function for use in a bioartificial liver (BAL).
33  to pig hepatocytes after treatment with the bioartificial liver (BAL).
34                                          The BioArtificial liver (UCLBAL) improved important prognost
35 art of an extracorporeal system, such as the bioartificial liver assist device, or an implantable tis
36                     This is a key advance in bioartificial liver development.
37 corporating the hepatocyte-like cells into a bioartificial liver device to treat fulminant hepatic fa
38  limitations of novel technologies including bioartificial liver devices and auxiliary liver transpla
39              This has prompted the design of bioartificial liver devices to "bridge" patients until t
40 l hepatology and cell-based therapies (e.g., bioartificial liver devices).
41 ion of cryopreserved isolated hepatocytes in bioartificial liver devices.
42  therapies for liver disorders or for use in bioartificial liver devices.
43 ned, implemented and tested a clinical-scale BioArtificial Liver machine containing a biomass derived
44                                            A BioArtificial Liver machine could temporarily replace th
45 heroids appear suitable for application in a bioartificial liver or as an in vitro liver tissue const
46                               Extracorporeal bioartificial liver support devices remain an exciting b
47                     Advances in the field of bioartificial liver support have led to an increasing de
48 ck, neither of which is likely to respond to bioartificial liver support or treatment with convention
49 olved in a phase I/II clinical trial using a bioartificial liver support system (BLSS), we proceeded
50                               Artificial and bioartificial liver support systems have thus far not de
51 atocyte cocultures, typically extracorporeal bioartificial liver support systems, are reviewed in the
52 ttempted by various approaches, for example, bioartificial liver support, extracorporeal pig liver pe
53 ll research may allow provision of cells for bioartificial liver support.
54 particularly for cell therapeutics including bioartificial liver systems (BALs).
55 he risk of viral exposure to patients during bioartificial liver therapy.
56 low fiber membranes, such as those used in a bioartificial liver, block the transfer of PERV.
57           Over the years, the development of bioartificial liver-assist devices has aimed at replacin
58 g or metabolic studies, and development of a bioartificial liver.
59 ery, and therapeutic applications, such as a bioartificial liver.
60 as drug screening, toxicological studies, or bioartificial livers are reliant on hepatocyte functiona
61 ause of the potential to use these cells for bioartificial livers, as a vehicle for gene transfer, an
62         Looking ahead, current challenges in bioartificial lung engineering include creation of ideal
63 , current challenges and ongoing research in bioartificial lung engineering.
64                                  Engineering bioartificial lung grafts from patient-derived cells cou
65                                Creation of a bioartificial lung requires engineering of viable lung a
66 esults support the application of engineered bioartificial matrices to promote vascularization for di
67 althy hematopoietic progenitor cells (HPCs), bioartificial matrixes from rat tail or purified human c
68            Here we show that HLOs required a bioartificial microporous poly(lactide-co-glycolide) (PL
69 thod for delivery of rVEGF using implantable bioartificial muscle (BAM) tissues made from genetically
70 al applications in biocompatibility studies, bioartificial muscle engineering, skeletal muscle differ
71 e centimeter large, few hundred micron-thick bioartificial muscle tissues composed of viable, dense,
72 tal muscle cells were tissue engineered into bioartificial muscles and flown in perfusion bioreactors
73 tive to allotransplantation, patient-derived bioartificial myocardium could provide functional suppor
74  into biomaterials has engendered the use of bioartificial nerve conduits as an alternative to autolo
75 ing the rate and extent of regeneration, the bioartificial nerve graft holds great promise for improv
76 c advances leading to the development of the bioartificial nerve graft.
77  was achieved by introducing MuSCs into a 3D bioartificial niche comprised of a thin sheet of mouse m
78 se interface approach to study the design of bioartificial organ scaffold architectures.
79 ace geometries, such as those encountered in bioartificial organ scaffold design.
80 ish the biosafety of this device and related bioartificial organ systems, these analyses support the
81  metabolic responses in several microfluidic bioartificial organs (liver, kidney, and cocultures), as
82                                 Microfluidic bioartificial organs enable the spatial and temporal con
83 ors, diagnostic devices, catalysts, and even bioartificial organs.
84 ionality and safety of the first stent-based bioartificial pancreas (BAP) device implanted endovascul
85                       Glycemic efficacy of a bioartificial pancreas based on insulin-secreting entero
86 afe transplantation of porcine islets with a bioartificial pancreas device in diabetic primates witho
87  cell-derived insulin-producing cells (i.e., bioartificial pancreas devices) may achieve a functional
88 ic capacity of generic and user-programmable bioartificial pancreas devices, which accounts for highl
89                                  A desirable bioartificial pancreas should be easy to implant, biopsy
90 ntial of this novel hybrid model to create a bioartificial pancreas to treat type 1 diabetes is tanta
91                                   Beyond the bioartificial pancreas, this work provides a framework f
92 h a challenge in the case of generation of a bioartificial pancreas, we have combined fluorine magnet
93 ransplantation, in particular by fabricating bioartificial pancreatic islets in vitro.
94 such as oxygen supply, in the engineering of bioartificial pancreatic islets to ensure their viabilit
95 oach to prepare highly viable and functional bioartificial pancreatic islets.
96                              Implantation of bioartificial patches distorts myocardial geometry, and
97                                     Although bioartificial support systems are under active investiga
98                              With the liquid bioartificial tissue compound used in this study, we ach
99                                   Injectable bioartificial tissue restores the heart's geometry and f
100 ring, we developed a mechanically responsive bioartificial tissue that responds to mechanical loading
101 e for the design and in vitro cultivation of bioartificial tissues, we have developed a multiscale co
102 lantation survival of thick, prevascularized bioartificial tissues.

 
Page Top